Turning Point tracks an impressive ORR rate in NSCLC — but shares skid lower on second look
CHICAGO — Fresh off of a $166 million IPO raise, Turning Point Therapeutics $TPTX joined the opening-day festivities at ASCO with an update on their lead drug repotrectinib — which they plan to pitch for an early approval for ROS1+ advanced non-small cell lung cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.